文献速递多重用药老年综合评估衰弱、肌少症与跌倒

多重用药与认知和身体能力的关联:一项英国出生队列研究

Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study.
PubMed 文献 · J Am Geriatr Soc · 2018-03-24

该研究基于英国出生队列,在69岁人群中发现多重用药(5-8种处方药,占18.2%)和过度多重用药(≥9种,占4.7%)与较差的认知和身体能力相关,且在校正疾病负担后仍存在。长期多重用药(60-64岁及69岁均存在)的负向关联更强,提示累积剂量依赖性关系。

要点

  • 69岁时多重用药和过度多重用药与较差的认知和身体能力相关,且独立于疾病负担。
  • 60-64岁和69岁均有多重用药者,其认知和身体能力的负向关联更强。
  • 未来研究应考虑在较年轻时减少多重用药的持续时间和水平,以改善认知和身体能力。

核心结论

  • 60-64岁和69岁时的多重用药与较差的认知和身体能力相关,即使校正疾病负担后仍存在。
  • 长期多重用药者的负向关联更强,提示累积剂量依赖性关系,剂量为处方药数量。

研究设计与样本

  • 前瞻性出生队列研究,样本来自英国医学研究理事会全国健康与发展调查,69岁时有用药数据的合格样本N=2,122(79%)。

主要发现

  • 69岁时多重用药(5-8种处方药)占18.2%,过度多重用药(≥9种)占4.7%。
  • 在校正性别、教育和疾病负担的模型中,多重用药和过度多重用药均与较差的认知和身体能力相关。
  • 过度多重用药的关联更强,例如与无多重用药相比,平均ACE-III评分差异:多重用药=-2.0(95%CI=-2.8至-1.1),过度多重用药=-2.9(95%CI=-4.4至-1.4)。
  • 60-64岁和69岁均有多重用药者,其与认知和身体能力的负向关联更强,例如平均坐立速度差异:两个年龄均有多重用药 vs 无多重用药=-3.9(95%CI=-5.2至-2.6),仅60-64岁有多重用药=-2.5(95%CI=-4.1至-0.9)。

关键数值与推荐

  • 多重用药定义为5-8种处方药,过度多重用药定义为≥9种处方药。
  • 认知能力评估采用词语学习测试、视觉搜索速度任务和Addenbrooke认知检查第三版(ACE-III)。
  • 身体能力测量采用坐立速度、站立平衡时间、步行速度和握力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate longitudinal associations between polypharmacy and cognitive and physical capability and to determine whether these associations differ with cumulative exposure to polypharmacy. DESIGN: Prospective birth cohort study. SETTING: England, Scotland, and Wales. PARTICIPANTS: An eligible sample of men and women from the Medical Research Council National Survey of Health and Development with medication data at age 69 (N=2,122, 79%). MEASUREMENTS: Cognitive capability was assessed using a word learning test, visual search speed task, and the Addenbrooke's Cognitive Examination, Third Edition (ACE-III). Physical capability was measured using chair rise speed, standing balance time, walking speed, and grip strength. RESULTS: Polypharmacy (5-8 prescribed medications) was present in 18.2% of participants at age 69 and excessive polypharmacy (≥9 prescribed medications) in 4.7%. Both were associated with poorer cognitive and physical capability in models adjusted for sex, education, and disease burden. Stronger associations were found for excessive polypharmacy (e.g., difference in mean ACE-III scores comparing polypharmacy=-2.0, 95% CI=-2.8 to -1.1 and excessive polypharmacy=-2.9, 95% CI=-4.4 to -1.4 with no polypharmacy). Participants with polypharmacy at age 60 to 64 and at age 69 showed stronger Negative associations with cognitive and physical capability were stronger still in participants with polypharmacy at both age 60 to 64 and at age 69 (e.g. difference in mean chair rise speed, comparing polypharmacy with no polypharmacy at both ages=-3.9, 95% CI=-5.2 to -2.6 and at age 60-64 only=-2.5, 95% CI=-4.1 to -0.9). CONCLUSION: Polypharmacy at age 60 to 64 and age 69 was associated with poorer physical and cognitive capability, even after adjusting for disease burden. Stronger negative associations were seen in participants with longstanding polypharmacy, suggesting a cumulative, dose-dependent relationship (where dose is the number of prescribed medications). Future research aiming to improve cognitive and physical capability should consider interventions to reduce the duration and level of polypharmacy at younger ages, in addition to optimizing disease control with appropriate medications.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Rawle MJ, Cooper R, Kuh D, et al. Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study. J Am Geriatr Soc. 2018. PMID: 29574684. doi:10.1111/jgs.15317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。